Press release
Investigation for Investors in shares of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) announced
An investigation for investors in EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) shares over potential securities laws violations.
Investors who purchased shares of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) concerning whether a series of statements by EyeGate Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Waltham, MA based EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. EyeGate Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $2.68 million in 2019 to $0.012 million in 2020, and that its Net Loss increased from $7.09 million in 2019 to $8.17 million in 2020.
Shares of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) declined from over $12 per share in late 2019 to as low as $1.44 per share in August 2021.
On November 3, 2021, NASDAQ: EYEG shares closed at $1.98 per share.
Those who purchased shares of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in shares of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) announced here
News-ID: 2452317 • Views: …
More Releases from Shareholders Foundation
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
More Releases for EyeGate
Ocular Drug Delivery Technology Market Next Big Thing | Major Giants Allergan pl …
The Latest research coverage on Ocular Drug Delivery Technology Market provides a detailed overview and accurate market size. The study is designed considering current and historical trends, market development and business strategies taken up by leaders and new industry players entering the market. Furthermore, study includes an in-depth analysis of global and regional markets along with country level market size breakdown to identify potential gaps and opportunities to better investigate…
Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.
Investors who purchased shares of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. officers and…
Novel Ocular Drug Delivery Devices Market Business Growth and Opportunities with …
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system.
The three primary methods of delivery of ocular medications to the eye are topical, local ocular (ie, subconjunctival, intravitreal, retrobulbar, intracameral), and systemic. The most appropriate method…
Global Uveitis Treatment Market 2020 Novartis, Valeant Pharmaceutical Internatio …
The report "Global Uveitis Treatment Market" evaluates the present and future market opportunities of Uveitis Treatment business. The analysis study sheds lightweight on a number of the main drivers and restraints factors influencing the expansion of the Uveitis Treatment market. The market is separate on the idea of product sort, Uveitis Treatment makers, application, and countries. practicableness of investment study, Uveitis Treatment market standing from 2015 to 2020, Uveitis Treatment…
Uveitis Treatment Market With Major Key Companies AbbVie, Novartis AG, Eyegate P …
The global uveitis treatment market was valued at US$ 555.51 Mn in 2016 and is expected to exhibit a robust CAGR of 6.0% over the forecast period (2017–2025).
Uveitis refers to inflammation caused in the uvea of the eye. A uvea is the middle layer of the eye that consists of three components namely iris, cilliary body, and the choroid. Uveitis is caused by various factors such as inflammatory diseases, injuries…
Macular Edema - Pipeline Review, H2 2018 | EyeGate Pharmaceuticals, Lupin, Mabio …
A new independent 50 page research with title 'Macular Edema - Pipeline Review, H2 2018' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Coherus BioSciences Inc, EyeGate Pharmaceuticals Inc, Lupin Ltd, Mabion SA, OMEICOS Therapeutics GmbH, Promedior Inc, Taiwan Liposome Company Ltd, Xbrane Biopharma AB. With n-number of tables and figures examining the Macular Edema,…
